Related Experiment Video
Updated: Apr 25, 2026
03:43
Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
Published on: August 22, 2025
754
Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice
Ester Aso1, Alexandre Sánchez-Pla2, Esteban Vegas-Lozano3
1Institut de Neuropatologia, Servei d'Anatomia Patològica, IDIBELL-Hospital Universitari de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Spain CIBERNED, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, Instituto Carlos III, Spain.
Journal of Alzheimer'S Disease : JAD
|August 16, 2014
Summary
Cannabis compounds delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) improved memory and reduced learning deficits in an Alzheimer
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- Alzheimer's disease (AD) pathology involves amyloid-beta (Aβ) plaques and neuroinflammation.
- The endogenous cannabinoid system is a potential therapeutic target for AD.
- Cannabis-derived compounds like THC and CBD have shown therapeutic potential.
Purpose of the Study:
- To investigate the therapeutic effects of THC and CBD, individually and in combination, on Alzheimer's disease.
- To evaluate the impact of these cannabinoids on cognitive function, Aβ pathology, and neuroinflammation in a mouse model of AD.
- To explore the molecular mechanisms underlying cannabinoid-induced neuroprotection.
Main Methods:
- Administration of THC, CBD, or a combination of both to AβPP/PS1 transgenic mice during the early symptomatic stage.
- Assessment of cognitive function using memory and learning tests.
- Analysis of brain tissue for Aβ peptide levels, plaque composition, astrogliosis, microgliosis, and inflammatory markers.
- Genome-wide gene expression profiling to identify molecular targets.
Main Results:
- THC and CBD, particularly in combination, preserved memory and reduced learning impairment in AD mice.
- The THC + CBD treatment significantly decreased soluble Aβ42 peptide levels and altered plaque composition.
- Cannabinoid treatment reduced neuroinflammation, including astrogliosis and microgliosis, with the combination showing the most pronounced effects.
- Gene expression analysis identified thioredoxin 2 and Wnt16 as key molecular targets of THC + CBD treatment.
Conclusions:
- The combination of THC and CBD demonstrates a superior therapeutic profile compared to individual components for Alzheimer's disease.
- Cannabinoids, through anti-inflammatory actions and modulation of Aβ pathology, offer a promising therapeutic strategy for AD.
- Further research into cannabis-based medicines is warranted for the potential treatment of Alzheimer's disease.
